HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Comparative study of isosorbide dinitrates and mononitrates in patients with ischemic heart disease and stable angina pectoris caused by stenosing coronary atherosclerosis].

Abstract
In an open clinical trial 19 patients with angina pectoris (functional class II-III) received in turn either non-retard tablets of isosorbide dinitrate (nitrosorbid, cardiket) in a mean dose 80 mg/day or isosorbide 5-mononitrate (mono mac) in a mean dose 51.5 mg/day. Each drug was given for a month. The effect was assessed by changes in frequency of anginal attacks and exercise tolerance. Non-retard isosorbide dinitrate and isosorbide 5-mononitrate demonstrate a good antiischemic effect, are safe and well tolerated. Isosorbide dinitrate and mononitrates do not differ significantly in reduction of the anginal attacks and by an increase in exercise tolerance but the effective dose of mono mac was 1.5-2 times less than that of nitrosorbide or cardiket, thus it is more cost-effective.
AuthorsV P Lupanov, I A Alekseeva, N N Vasil'eva, Kh Kh Chotchaev, V G Naumov
JournalKlinicheskaia meditsina (Klin Med (Mosk)) Vol. 78 Issue 9 Pg. 52-5 ( 2000) ISSN: 0023-2149 [Print] Russia (Federation)
Vernacular TitleSravnitel'noe izuchenie izosorbida di- i mononitratov u bol'nykh ishemicheskoĭ bolezn'iu serdtsa so stabil'noĭ stenokardieĭ, obuslovlennoĭ stenoziruiushim koronarnym aterosklerozom.
PMID11051743 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Vasodilator Agents
  • Isosorbide Dinitrate
  • isosorbide-5-mononitrate
Topics
  • Aged
  • Angina Pectoris (complications, drug therapy, economics)
  • Coronary Artery Disease (complications, drug therapy, economics)
  • Coronary Disease (complications, drug therapy, economics)
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Isosorbide Dinitrate (analogs & derivatives, economics, therapeutic use)
  • Male
  • Middle Aged
  • Myocardial Ischemia (complications, drug therapy, economics)
  • Vasodilator Agents (economics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: